MAT Waiver Training

Helping states connect the dots to more effectively address opioid use disorders

Date: Wednesday, March 8, 2017
Time: 8:30 am - 5:30 pm CT (Lunch will be provided, please email sara.holifield@tnpca.org with any special dietary requirements.)
Location: Tennessee Primary Care Association
710 Spence Lane, Nashville, TN
Presenter: Stephen Wyatt, DO, FASAM, FAOAAM
Bring: Photo ID
Cost: No fee

Sponsoring DATA 2000
Organization: American Academy of Addiction Psychiatry

Register Now
http://www.cvent.com/d/rfqh6c

About the waiver training

Medication assisted treatment waiver training is available for physicians, nurse practitioners, and physician assistants interested in seeking to apply for their waiver to prescribe buprenorphine in the treatment of opioid use disorders. To obtain the waiver to prescribe buprenorphine, providers are required to take eight hours of training.

Following trainings, participants who have successfully completed the course, may apply to the Substance Abuse and Mental Health Services Administration (SAMHSA) to obtain the waiver. PCSS-MAT urges all those who complete the course to submit a Notice of Intent Form to SAMHSA to obtain a waiver to prescribe. The waiver must be completed online and a link to the online form will be provided to participants following the training.

PCSS-MAT has a comprehensive library of materials (many are designated for AMA PRA Category 1 Credit™) available at no cost created to give healthcare providers confidence in treating their patients more effectively. PCSS-MAT also has a no-cost clinical coaching/mentoring program to provide one-on-one clinical expertise for primary care providers.

Helpful Resources

Buprenorphine Waiver Training
Advanced Review Module
Help with the NOI form (PPT)
How to Prepare for a DEA Inspection
DEA Inspection References
Upcoming PCSS-MAT webinars
Archived PCSS-MAT webinars
PCSS-MAT Modules

Questions? Email Seth Acton (seth@aaap.org).

Residents may take the course and apply for their waiver when they receive their DEA license. Nurse practitioners (NPs) and physician assistants (PAs) may take the 8-hour waiver course and apply it toward the 24-hour training requirement established by the Comprehensive Addiction and Recovery Act. For the additional 16 hours, SAMHSA will also offer the training for free through PCSS-MAT in early February, 2017, and through other organizations. NPs and PAs who have completed the required training and seek to become DATA-waivered for up to 30 patients will be able to apply to do so in early 2017. For more information on this initiative and SAMHSA-sponsored training opportunities, sign up for the Buprenorphine Waiver Management email list.

CME Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AAAP and Tennessee Primary Care Association.

Credit Designation: American Academy of Addiction Psychiatry designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of physician participation in the learning process: Credit will only be awarded for completing all of the training. To be awarded a maximum of 8 AMA PRA Category 1 Credits™ and a Buprenorphine Training Completion Certificate you must complete all 8 hours of the course and receive a minimum cumulative score of 75% on the examination. Those passing the course will be able to complete the waiver application online.

Funding for this initiative was made possible (in part) by Providers’ Clinical Support System for Medication Assisted Treatment (SU79T1024697) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.